

Listing of the Claims:

1. (Cancelled)
2. (Previously Presented) The method of claim 11 wherein the newborn subject is a mammal in the first four weeks after birth.
3. (Currently Amended) The method of claim 11 wherein the newborn ~~or fetal~~ subject is a human.
4. (Cancelled)
5. (Previously Presented) The method of claim 11 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.
6. (Previously Presented) The method of claim 11 wherein the medicament is in gaseous form.
7. (Cancelled)
8. (Previously Presented) The method of claim 11 wherein the medicament is in liquid form.
9. (Cancelled)
10. (Cancelled)
11. (Previously Presented) A method of providing analgesia in a newborn subject, the method comprising administering to a newborn subject in need of analgesia a therapeutically effective amount of xenon.
12. (Previously Presented) A method of providing analgesia in a fetal subject, the method

comprising administering to the mother of the fetal subject, the fetal subject in need of analgesia, a therapeutically effective amount of xenon the fetal subject.

13. (Previously Presented) A method accordingly to claim 11 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

14. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

15. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a lipid emulsion.

16. (Previously Presented) A method according to claim 11 wherein the xenon is administered intraveneously, neuraxially or transdermally.

17. (Previously Presented) A method accordingly to claim 12 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

18. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

19. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a lipid emulsion.

20. (Previously Presented) A method according to claim 12 wherein the xenon is administered intraveneously, neuraxially or transdermally.

21. (Previously Presented) The method according to claim 12, wherein the xenon is administered to the mother prior to labor.

PATENT
Serial No. 10/524,316
02839/46401

22. (Previously Presented) The method according to claim 12, wherein the xenon is administered to the mother during labor.

23. (Previously Presented) The method of claim 5, wherein the further analgesic agent is an alpha-2-adrenergic agonist, an opiate, or a non-steroidal anti-inflammatory drug.

24. (Previously Presented) The method of claim 5, wherein the sedative or anaesthetic agent promotes GABAergic activity.